COLL Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -3.81%, SMA50 -5.55%, SMA200 15.38%). The stock’s 14-day RSI is 40.84 (neutral), while the ATR of 1.64 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -12.93% below its high and over 90.36% above its low. Average 10-day trading volume of 785.24 thousand shares is significantly above the 3-month average of 477.11 thousand, indicating heightened recent market interest.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) closed at $33.23 USD, losing -$1.51 (-4.33%) from the previous close of $34.73. The stock is currently mid-range between its 52-week high and low $23.23 and $50.79. With a market capitalization of about $1.06 billion, Collegium Pharmaceutical, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.68). Key stats such as the average daily volume over the past year has been around 489.55 thousand shares, in line with its 52-week average. Headquartered in Stoughton, MA, Collegium Pharmaceutical, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Vikram Karnani, the company employs approximately 357 people and listed since May 07, 2015. Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management.

Collegium Pharmaceutical, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $17.38. This means the shares are trading above this model’s fair value.

Collegium Pharmaceutical, Inc. has 31.50 million shares outstanding. The public float is 28.10 million shares, elevated short interest at 16.45% of float. This equals 4.32 million shares. The short ratio is 10.26 days. Institutional investors hold 118.66% of the float. Insiders own 1.72%. Rubric Capital Management LP holds 3.13 million shares, Ciaffoni Joseph has 275.00 thousand shares and Fleming Alison B has 148.75 thousand shares. Over the past six months, insider transactions show net selling. They sold 67.37 thousand shares across 6 transactions.

Wall Street analysts project EPS growth of 7.7% annually over the next five years. The latest quarter delivered EPS of $0.80. The next quarter is forecast at $2.13. Next year's EPS is expected at $12.61. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 11 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $60.00 to $44.00. The high target offers 80.56% upside. The low target suggests 32.41% downside. The mean target is $52.62. This offers 58.35% upside. Collegium Pharmaceutical, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -57.5%. The prior quarter beat by 3.7%. Over the last six quarters, Apple has recorded several small beats. These include 3.85% in August 08, 2024.

Collegium Pharmaceutical, Inc. trades at a P/E ratio of 16.76, slightly below the S&P 500 average, with a price-to-sales ratio of 1.35 and a price-to-book ratio of 3.49 trading at moderately above to book value. The P/FCF stands at 3.22, also below market averages.

Our AI price prediction model suggests that Collegium Pharmaceutical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -13.51%, with price expected at $28.74 by April 06, 2026, within a range of $27.27 to $30.30 3-Month Outlook: Projected fall of -11.8%, reaching $29.31 by June 19, 2026, with a range of $27.64 to $30.57. 1-Year Outlook: Projected gain of 27.38%, with price at $42.33 by March 23, 2027, within a range of $40.71 to $44.47.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shares are flat 3.02% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Collegium Pharmaceutical, Inc. trading at a premium to the broader market with a P/E of 16.76. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $38.30, suggesting 15.26% upside. Our AI forecast model points to short-term weakness (-13.51% over two weeks), a medium-term fall (-11.8% over three months), and a longer-term gain (27.38% over one year), with expected trading ranges indicating moderate volatility.